A
Anthem Biosciences Ltd
NSE:ANTHEM
Anthem Biosciences Ltd
NSE:ANTHEM
Price:
729.95
INR
-1.94%
Market Closed
Market Cap:
₹410B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
IN |
|
Stellus Capital Investment Corp
NYSE:SCM
|
US |
|
I.A Group Corp
TSE:7509
|
JP |
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
US |
|
Matsui Securities Co Ltd
TSE:8628
|
JP |
|
T
|
Turcas Petrol AS
IST:TRCAS.E
|
TR |
|
C
|
China Starch Holdings Ltd
HKEX:3838
|
HK |
|
CITech Co Ltd
KRX:004920
|
KR |
|
Computer Age Management Services Ltd
NSE:CAMS
|
IN |
|
Ajmera Realty & Infra India Ltd
NSE:AJMERA
|
IN |
|
Aditya Birla Capital Ltd
BSE:540691
|
IN |
|
E
|
ELK-Desa Resources Bhd
KLSE:ELKDESA
|
MY |
|
Titan Company Ltd
NSE:TITAN
|
IN |
|
Redcentric PLC
LSE:RCN
|
UK |
Balance Sheet
Balance Sheet Decomposition
Anthem Biosciences Ltd
Anthem Biosciences Ltd
Balance Sheet Decomposition is not available for
Anthem Biosciences Ltd
Anthem Biosciences Ltd
Balance Sheet
Anthem Biosciences Ltd
Anthem Biosciences Ltd
Currency: INR
| Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|
| Assets | ||||
| Cash & Cash Equivalents |
3 428
|
1 844
|
3 170
|
|
| Cash |
6
|
5
|
8
|
|
| Cash Equivalents |
3 422
|
1 839
|
3 161
|
|
| Short-Term Investments |
4 929
|
4 591
|
4 161
|
|
| Total Receivables |
2 753
|
4 906
|
4 599
|
|
| Accounts Receivables |
2 742
|
4 906
|
4 504
|
|
| Other Receivables |
11
|
0
|
95
|
|
| Inventory |
1 325
|
2 240
|
3 557
|
|
| Other Current Assets |
796
|
1 234
|
1 879
|
|
| Total Current Assets |
13 232
|
14 816
|
17 367
|
|
| PP&E Net |
6 039
|
8 210
|
9 981
|
|
| PP&E Gross |
6 039
|
8 210
|
9 981
|
|
| Accumulated Depreciation |
4 199
|
4 940
|
5 737
|
|
| Intangible Assets |
91
|
62
|
39
|
|
| Note Receivable |
116
|
118
|
100
|
|
| Long-Term Investments |
105
|
183
|
234
|
|
| Other Long-Term Assets |
562
|
592
|
354
|
|
| Total Assets |
20 145
N/A
|
23 981
+19%
|
28 076
+17%
|
|
| Liabilities | ||||
| Accounts Payable |
719
|
1 007
|
1 101
|
|
| Accrued Liabilities |
214
|
275
|
197
|
|
| Short-Term Debt |
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
292
|
1 226
|
634
|
|
| Other Current Liabilities |
413
|
879
|
1 331
|
|
| Total Current Liabilities |
1 639
|
3 386
|
3 262
|
|
| Long-Term Debt |
970
|
1 160
|
499
|
|
| Other Liabilities |
130
|
189
|
216
|
|
| Total Liabilities |
2 738
N/A
|
4 735
+73%
|
3 977
-16%
|
|
| Equity | ||||
| Common Stock |
1 141
|
1 118
|
1 118
|
|
| Other Equity |
16 266
|
18 128
|
22 980
|
|
| Total Equity |
17 407
N/A
|
19 247
+11%
|
24 099
+25%
|
|
| Total Liabilities & Equity |
20 145
N/A
|
23 981
+19%
|
28 076
+17%
|
|
| Shares Outstanding | ||||
| Common Shares Outstanding |
562
|
562
|
562
|
|
Switch to:
Switch to:
See Also
Discover More
